At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 283 enrolled
Drug / intervention
Ranibizumab 0.5 mg +1 moredrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]
In Brief
A Phase 3 clinical trial evaluating Ranibizumab 0.5 mg and Sham injection for Macular Edema Secondary to Branch Retinal Vein Occlusion. Completed, enrolled 283 participants across 33 sites in 6 countries.
Detailed Summary
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Hong Kong, Indonesia, Philippines, Taiwan, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartNov 2013
Primary CompletionMar 2016
TodayJul 2026
First PostedNov 5, 2013
Enrollment StartNov 12, 2013
Primary CompletionMar 28, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.7 years ago
Interventions
Ranibizumab 0.5 mgdrug
intravitreal injection of 0.05 ml
Sham injectionother
Sham intravitreal injection